Chief Medical and Development Officer — Yong Ben, M.D., M.B.A.: The Chief Medical and Development Officer is resigning, which is a genuine departure of a senior officer, but the notice period and lack of stated disagreement suggest an orderly exit rather than a crisis.

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be exp…

Director — Michelle Doig: The resignation of a Class I director upon the completion of their term at the annual meeting is a routine board turnover event, not a loss of a senior executive officer.

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be exp…

CEO — Eli Wallace: The CEO resigned but was immediately succeeded by a named successor (Pedro J. Beltran) who also assumed the role, constituting an orderly succession rather than a sudden loss of leadership.

CEO — Pedro Beltran: The CEO position was filled by an internal promotion (Chief Scientific Officer to CEO) with an immediate successor, representing an orderly succession rather than a sudden loss of leadership.

Director — Peter Lebowitz, M.D., Ph.D.: The filing discloses the appointment of a new independent director to fill a vacancy created by a board size increase, which is a routine governance action rather than an executive departure.

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be exp…

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be exp…

Regulation FD Disclosure. On August 11, 2025, PubCo issued a press release announcing the completion of the Business Combination and the first day of trading on Nasdaq, a copy of which is furnished as Exhibit 99.4 hereto. The information in this Item 7.01, including Exhibit 99.4, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the fi…

of this Current Report concerning the issuance and sale by PubCo of certain unregistered securities, which is incorporated herein by reference. Description of Registrant’s Securities to be Registered The description of the securities of PubCo is included in the Proxy Statement/Prospectus in the section titled “ Description of PubCo Securities ,” which is incorporated herein by reference. Indemnification of Directors and Officers The disclosure set forth in

The excerpt is a generic cross-reference to proxy statement sections rather than a specific disclosure of a management change event.

Change in Registrant’s Certifying Accountant (a) Dismissal of independent registered public accounting firm. On August 11, 2025, PubCo Board dismissed WithumSmith+Brown, PC (“Withum”), the independent registered public accounting firm of Helix prior to the Business Combination, as the independent registered public accounting firm of PubCo. The report of Withum on the financial statements of Helix as of December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, and was no…

Entry into a Material Definitive Agreement A&R Registration Rights Agreement In connection with the Closing, the Helix Insiders, certain BBOT Stockholders and PubCo entered into an amended and restated registration rights agreement (“A&R Registration Rights Agreement”). Pursuant to the A&R Registration Rights Agreement, among other things, PubCo agreed that, within 30 calendar days following the Closing Date, PubCo will file with the SEC (at PubCo’s sole cost and expense) a registration state…

Material Modification to Rights of Security Holders In connection with the consummation of the Business Combination, Helix migrated and domesticated as a Delaware corporation, changed its name to “BridgeBio Oncology Therapeutics, Inc.” and adopted the PubCo Charter and new bylaws (the “PubCo Bylaws”). Reference is made to the disclosure in the Proxy Statement/Prospectus in the sections titled “ The Domestication Proposal ,” “ Proposal 2: The Domestication Proposal ,” “ Organizational Document…

Changes in Control of Registrant Reference is made to the disclosure in the Proxy Statement/Prospectus in the section titled “ Proposal No. 1: The Business Combination Proposal,” which is incorporated herein by reference. The information set forth in the section titled “Introductory Note” and in the section titled “Security Ownership of Certain Beneficial Owners and Management” in

of this Current Report. A more complete summary of the material provisions of the Business Combination Agreement is included in the Proxy Statement/Prospectus in the section titled “ Proposal No. 1: The Business Combination — Structure of the Business Combination ”. That summary and the description of the Business Combination Agreement included in this Current Report are qualified in their entirety by reference to the full text of the Business Combination Agreement, a copy of which is filed a…

Regulation FD Disclosure. On July 11, 2025, Helix Acquisition Corp. II (the “ Company ” or “ Helix ”) and TheRas, Inc (d/b/a BridgeBio Oncology Therapeutics) (“ BBOT ”) jointly issued a press release announcing, among other things, that the Registration Statement on Form S-4 (as amended, the “ Registration Statement ”) filed by Helix and BBOT, in connection with the previously-announced business combination among Helix, BBOT and the other parties thereto, has been declared effective by the U.…

Entry into a Material Definitive Agreement. Business Combination Agreement On February 28, 2025, Helix Acquisition Corp. II, a Cayman Islands exempted company (“ Helix ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”) by and among Helix, TheRas, Inc., a Delaware corporation (doing business as BridgeBio Oncology Therapeutics, “ BBOT ”), and Helix II Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Helix (“ Merger Sub ”). The Bus…

Unregistered Sales of Equity Securities. The disclosure set forth above in

Regulation FD Disclosure. On February 28, 2025, Helix Acquisition Corp. II (“Helix II”) and TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics (“BBOT”)), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K a malignancies, issued a joint press release announcing the execution of a business combination agreement (the “Business Combination Agreement”) relating to a proposed business combination (…

Director — Albert A. Holman, III: The filing discloses the appointment of a new independent director to the board of a SPAC, which is a routine governance event and not an executive departure.

Other Events. As previously reported, on February 13, 2024, Helix Acquisition Corp. II (the “ Company ”) consummated its initial public offering (the “ IPO ”) of 18,400,000 Class A ordinary shares, par value $0.0001 per share (the “ Class A Ordinary Shares ”), including the issuance of 2,400,000 Class A Ordinary Shares as a result of the underwriter’s exercise in full of its over-allotment option. The Class A Ordinary Shares were sold at a price of $10.00 per share, generating gross proceeds…

Entry into Material Definitive Agreement. On February 13, 2024, Helix Acquisition Corp. II (the “ Company ”) consummated its initial public offering (the “ IPO ”) of 18,400,000 Class A ordinary shares, par value $0.0001 per share (the “ Class A Ordinary Shares ”), including the issuance of 2,400,000 Class A Ordinary Shares as a result of the underwriter’s exercise in full of its over-allotment option. The Class A Ordinary Shares were sold at a price of $10.00 per share, generating gross proce…

Other Events. A total of $184,000,000 comprised of the net proceeds from the IPO and the sale of the Private Placement Shares were placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds in the trust account that may be released to the Company to pay its taxes and up to $100,000 of interest to pay dissolution expenses, the funds held in the trust account will not be released from the…